Dr. David Rimm, a pathologist who specializes in tissue biomarker assessment in cancer, was recently appointed the Anthony N. Brady Professor of Pathology.
Dr. Rimm is a professor in the Department of Pathology at Yale School of Medicine. He earned his M.D. and Ph.D. degrees at Johns Hopkins University Medical School followed by a pathology residency at Yale and a Cytopathology Fellowship at the Medical College of Virginia. He is board certified in anatomic pathology and cytopathology.
At Yale since 1994, Dr. Rimm is the director of Yale Pathology Tissue Services. He also serves as the Director of Translational Pathology and the director of the Physician Scientist Training program in Pathology. His lab group focuses on quantitative pathology using the AQUA® technology invented in his lab, and other quantitative approaches with projects related to predicting response to therapy or recurrence in breast and lung cancer and melanoma and head and neck squamous cell carcinoma. The lab also works on issues related to biospecimen science, especially assay standardization. For discovery of new biomarkers, the lab uses high-plex technologies, including Imaging mass cytometry and digital spatial profiling. The work is supported by grants from the National Institutes of Health, the Breast Cancer Research Foundation, and sponsored research agreements from biotech and pharma.
Dr. Rimm serves on the Immunohistochemistry committee for the College of American Pathologists (CAP), the AJCC 9th Edition Panel for Tumor Staging in Breast Cancer and a number of guideline setting committees. He is an author of over 425 peer-reviewed papers and eight patents with an H-index of 110. He has served on advisory boards for Amgen, Lilly, Novartis, Astra Zeneca, BMS, Danaher, Cepheid, Perkin Elmer, Dako, Ventana, PAIGE.AI, and Cell Signaling Technology. He was a scientific co-founder of HistoRx, a digital pathology company (sold to Genoptix in 2012).